Redhill Biopharma Ltd. (RDHL) Expected to Announce Earnings of -$0.58 Per Share

Analysts forecast that Redhill Biopharma Ltd. (NASDAQ:RDHL) will report earnings of ($0.58) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Redhill Biopharma’s earnings, with estimates ranging from ($0.62) to ($0.51). Redhill Biopharma reported earnings of ($0.60) per share in the same quarter last year, which indicates a positive year-over-year growth rate of 3.3%. The company is expected to announce its next earnings results on Tuesday, July 25th.

According to Zacks, analysts expect that Redhill Biopharma will report full year earnings of ($2.23) per share for the current financial year, with EPS estimates ranging from ($2.35) to ($2.04). For the next fiscal year, analysts expect that the business will post earnings of ($2.23) per share, with EPS estimates ranging from ($2.40) to ($2.05). Zacks Investment Research’s EPS averages are an average based on a survey of sell-side research analysts that that provide coverage for Redhill Biopharma.

Redhill Biopharma (NASDAQ:RDHL) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.50) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.64) by $0.14.

A number of equities research analysts have recently weighed in on the stock. Zacks Investment Research downgraded shares of Redhill Biopharma from a “buy” rating to a “hold” rating in a research note on Wednesday, July 5th. FBR & Co restated a “buy” rating on shares of Redhill Biopharma in a research note on Friday, June 16th. HC Wainwright set a $33.00 price target on shares of Redhill Biopharma and gave the company a “buy” rating in a research note on Thursday, June 15th. Finally, Roth Capital set a $26.00 price target on shares of Redhill Biopharma and gave the company a “buy” rating in a research note on Thursday, May 4th.

A number of large investors have recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in Redhill Biopharma during the fourth quarter valued at approximately $4,087,000. Renaissance Technologies LLC increased its stake in Redhill Biopharma by 144.1% in the first quarter. Renaissance Technologies LLC now owns 62,000 shares of the biotechnology company’s stock valued at $595,000 after buying an additional 36,600 shares in the last quarter. Jane Street Group LLC acquired a new stake in Redhill Biopharma during the first quarter valued at approximately $276,000. Family Management Corp acquired a new stake in Redhill Biopharma during the first quarter valued at approximately $163,000. Finally, Bank of New York Mellon Corp acquired a new stake in Redhill Biopharma during the first quarter valued at approximately $101,000. Institutional investors and hedge funds own 12.31% of the company’s stock.

Redhill Biopharma (NASDAQ RDHL) traded up 3.28% during trading on Wednesday, reaching $8.81. 76,147 shares of the company’s stock were exchanged. The firm’s market cap is $149.83 million. The stock’s 50 day moving average price is $9.43 and its 200 day moving average price is $9.89. Redhill Biopharma has a 52-week low of $8.20 and a 52-week high of $16.54.

TRADEMARK VIOLATION NOTICE: This article was first reported by BBNS and is owned by of BBNS. If you are accessing this article on another website, it was illegally copied and reposted in violation of United States and international copyright law. The legal version of this article can be read at https://baseballnewssource.com/markets/redhill-biopharma-ltd-rdhl-expected-to-announce-earnings-of-0-58-per-share-updated/1204279.html.

About Redhill Biopharma

Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.

Get a free copy of the Zacks research report on Redhill Biopharma (RDHL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Redhill Biopharma (NASDAQ:RDHL)

Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with our FREE daily email newsletter.

 


Latest News

Giancarlo Stanton Continues Record Pace for July
Giancarlo Stanton Continues Record Pace for July
Los Angeles Dodgers Ace Clayton Kershaw to Go on DL
Los Angeles Dodgers Ace Clayton Kershaw to Go on DL
Colin Moran Fouls Ball Off Eye, Taken to Hospital
Colin Moran Fouls Ball Off Eye, Taken to Hospital
Chris Sale Reaches 200 Strikeouts in Record Time
Chris Sale Reaches 200 Strikeouts in Record Time
Veteran Pitcher Bartolo Colon Considering Retirement
Veteran Pitcher Bartolo Colon Considering Retirement
Todd Frazier Traded to Yankees for Blake Rutherford and Others
Todd Frazier Traded to Yankees for Blake Rutherford and Others


Leave a Reply

 
© 2006-2017 BBNS.